MycRX Pty Ltd is developing novel, small molecule therapeutics for the treatment of lung cancer.
MycRX is a privately-held biotechnology company based in Melbourne. Working with researchers at CSIRO and Peter MacCallum Cancer Centre (PMCC), we have used proprietary assays to develop multiple series of novel drug-like inhibitors of the oncoprotein Myc.
Myc is a transcription factor that drives expression of genes critical for cell growth, differentiation and metabolism and its dysregulation is implicated in >70% of all cancers. Their compounds represent a world-first in potently and selectively directly blocking Myc function.
This project will focus on developing the Myc inhibitors for the treatment of lung cancer, the fifth most common cancer diagnosed in Australia.
BTB Round: One
- MTPConnect Grant: $900,000
- Industry Contribution: $1,698,000
Duration: February 2020 – June 2021 (Finished)
Outcomes: MycRx built a comprehensive dataset optimising existing late lead compounds to candidate selection: safe and eﬀective Myc inhibitors with potent and selective activity, good PK properties in rodents, including oral bioavailability. In addition, the comprehensive dataset generated has resulted in a high-quality data package for commercialisation discussions with potential pharma and biotech partners as well as international venture capital firms.